Quinolines and derivatives
Medchemexpress LLC MHY1485 | 326914-06-1 | 99.9% | 200 MG
MHY1485 is a potent, cell-permeable mTOR activator that targets the ATP domain of mTOR. It inhibits autophagy by suppressing the fusion between autophagosomes and lysosomes.
- Inhibits GCDC-induced autophagic activity in HCC cells
- Increases LC3II/LC3I ratio in rat liver Ac2F cells
- Dose-dependently increases phosphorylation of mTOR at Ser2448 and upregulates 4E-BP1 phosphorylation in Ac2F cells
- Blocks autophagy signaling induced by follicle-stimulating hormone (FSH) in female ICR mice
- Increases p-mTOR and p-S6K1 expression levels in mice
Medchemexpress LLC Amifostine (trihydrate) | 112901-68-5 | 100.0% | 200 MG
Amifostine trihydrate is a broad-spectrum cytoprotective agent and radioprotector. It selectively protects normal tissues from damage caused by radiation and chemotherapy. It acts as a potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer, protecting cells by scavenging oxygen-derived free radicals. It also reduces renal toxicity and exhibits antiangiogenic action.
- Broad-spectrum cytoprotective agent
- Radioprotector
- Selectively protects normal tissues from radiation and chemotherapy damage
- Potent HIF-α1 and p53 inducer
- Scavenges oxygen-derived free radicals
- Reduces renal toxicity
- Exhibits antiangiogenic action
- Protects against tert-Butyl hydroperoxide (TBHP)-induced cell damage
- Reduces H9c2 cell apoptosis
- Provides protection against myocardial ischemia/reperfusion injury
Medchemexpress LLC Tropifexor | 1383816-29-2 | MFCD31693060 | 99.4% | 603.6 g/mol | C29H25F4N3O5S | 200 MG
Tropifexor is a non-bile-acid, small-molecule agonist of the farnesoid X receptor (FXR) with reported biochemical potency around EC50 ≈ 0.2 nM. Identified in medicinal chemistry studies and advanced into clinical development, it is used in research on cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). Available as a research reagent with reported high purity and defined analytical properties.
- Highly potent FXR agonist (EC50 ≈ 0.2 nM).
- Non-bile-acid small molecule suitable for biochemical and cellular assays.
- Reported high purity for research applications.
- Well characterized chemical properties for analytical workflows.
- Supported by published discovery and clinical development literature.
Apexbio Technology LLC Bitopertin(Synonyms: RG1678, RO4917838, RG-1678, RO-4917838), 200mg, CAS: 845614-11-1.
Bitopertin (CAS 845614-11-1) also known as RG1678 is a selective inhibitor of glycine transporter-1 (GlyT1) exhibiting an EC50 of 30 nM in vitro GlyT1 inhibition increases synaptic glycine a co-agonist at N-methyl-D-aspartate (NMDA) receptor glycine-binding sites thereby enhancing NMDA receptor-mediated glutamatergic neurotransmission This mechanism addresses glutamatergic dysfunction implicated in schizophrenia Clinical studies indicate that adjunctive bitopertin treatment improves negative symptoms in schizophrenia patients highlighting its therapeutic potential as a GlyT1-targeted research tool and drug candidate
Apexbio Technology LLC Tirapazamine(Synonyms: SR-4233, WIN 59075, Tirazone, TPZ, 3-Amino-1,2,4-benzotriazine 1,4-dioxide), 200mg, CAS: 27314-97-2.
Tirapazamine (CAS 27314-97-2) also known as SR259075 Win59075 or SR4233 is an investigational anticancer agent selectively activated under hypoxic conditions characteristic of solid tumors The compound is bioreduced in hypoxic tumor microenvironments to cytotoxic free radicals leading to cellular damage Tirapazamine downregulates hypoxia-inducible factor-1 (HIF-1 ) thereby influencing pathways associated with tumor adaptive mechanisms to hypoxia Combined treatment with tirapazamine and topoisomerase I inhibitors (such as SN-38 the active metabolite of irinotecan) enhances apoptosis via mitochondria-mediated caspase activation and weakened DNA repair signaling Preclinical investigations including hepatocellular carcinoma xenografts confirm this enhanced tumor suppression Clinical trials evaluating tirapazamine s anticancer efficacy are ongoing
Medchemexpress LLC HPV16 E7 (86-93) (TFA) | 98.0% | 929.06 | 10 MG
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide, immunogenic in cervical carcinomas. It is for research use only. Precursor T cells specific for the peptide are able to differentiate into HPV-specific effector cells. Peptide-loaded autologous dendritic cells can stimulate a specific cytotoxic CD8+ T-cell response.
- Specific T cells are expandable upon in vitro stimulation with peptide-pulsed dendritic cells.
- Response against K562 cells pulsed with the peptide was significantly blocked by anti-HLA class I Ab w6/32.
- Peptide in IVS culture shows specific T cell expansion.
- The peptide can induce cytotoxic T lymphocyte (CTL) responses if loaded on antigen presenting HLA class I molecules.
Medchemexpress LLC Tacalcitol monohydrate | 93129-94-3 | 99.9% | 434.65 | 5 MG
Tacalcitol monohydrate promotes normal bone growth by regulating calcium ions. It also inhibits cancer cell proliferation and migration. This compound is suitable for research related to inflammation, cancer, and skin diseases.
- Promotes normal bone growth through calcium ion regulation.
- Inhibits cancer cell proliferation and migration.
- Inhibits the synthesis of IL-6 and IL-8 in nasal polyp fibroblast cultures in a dose-dependent manner.
- Induces cell differentiation in normal human keratinocytes.
- Inhibits the growth of normal and psoriatic human keratinocytes.
- Inhibits DNA synthesis in normal human keratinocytes.
- Strongly reduces the proliferation of human glioblastoma.
- Inhibits human glioblastoma migration.
- Significantly inhibits TPA-induced cutaneous inflammation and improves epidermal differentiation in hairless mice.
Medchemexpress LLC Mirin | 1198097-97-0 | MFCD05885480 | 99.6% | 220.25 | 200 MG
Mirin | 1198097-97-0 | MFCD05885480 | 99.6% | 220.25 | 200 MG
Apexbio Technology LLC SKL2001 909089-13-0 200mg
SKL2001 (CAS 909089-13-0) is a small-molecule agonist that selectively activates the Wnt/ -catenin signaling pathway It functions by interfering with the interaction between Axin and -catenin thereby enhancing intracellular -catenin stability In cellular studies SKL2001 has been demonstrated to suppress cancer cell proliferation This compound is widely utilized in fundamental research investigating the molecular mechanisms of cancer and serves as a tool for drug discovery targeting the Wnt/ -catenin pathway
Apexbio Technology LLC N-Methylnicotinamide 114-33-0 200mg
N-Methylnicotinamide (CAS 114-33-0) is a methylated derivative of nicotinamide and a primary metabolic product of niacinamide and niacin (vitamin B3) catabolism It does not have a defined therapeutic target or approved clinical use but plays a significant role in biomedical research as an indicator of vitamin B3 status Measurement of urinary N-methylnicotinamide is routinely employed to assess niacin sufficiency and diagnose deficiencies reflecting metabolic function related to NAD/NADP biosynthesis pathways This compound thus serves as a valuable biomarker in nutritional and metabolic research contexts
Medchemexpress LLC Cilazapril monohydrate | 92077-78-6 | MFCD00865788 | 99.9% | C22H33N3O6 | 100 MG
Cilazapril monohydrate is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat. It functions by reducing plasma ACE activity. This compound can be utilized in the research of hypertension, including essential and renal hypertension, and congestive heart failure.
- Orally active prodrug of an ACE inhibitor
- Reduces plasma ACE activity
- Used in research of hypertension (essential and renal)
- Used in research of congestive heart failure
Medchemexpress LLC B7-H2/ICOSLG Mouse 5ug
B7-H2/ICOSLG is an important ligand of the T cell receptor ICOS and mediates immune responses It acts as a costimulatory signal promoting T and B cell proliferation cytokine secretion and plasma cell differentiation B7-H2/ICOSLG Protein Mouse (HEK293 His) is the recombinant mouse-derived B7-H2/ICOSLG protein expressed by HEK293 with C-His labeled tag
Medchemexpress LLC 4-(2,2-difluoro-1,3-benzodioxol-4-yl)-1H-pyrrole-3-carbonitrile | 131341-86-1 | MFCD01631158 | 98.0% | 248.19 g/mol | C12H6F2N2O2 | 200 MG
Fludioxonil is a phenylpyrrole fungicide supplied as an analytical standard (CAS 131341-86-1) for laboratory research and method development. The material is provided as a high-purity solid suitable for reference, calibration, and analytical assays.
- High purity (98.0%) suitable for analytical applications.
- Molecular formula C12H6F2N2O2 and molecular weight 248.19 g/mol.
- Supplied as a stable solid for reliable storage and handling.
- Suitable for method development, calibration, and reference standards.
- Compatible with HPLC and GC analytical techniques.
Medchemexpress LLC Orbifloxacin | 113617-63-3 | 99.8% | 200 MG
Orbifloxacin is an orally administrable antibiotic that disrupts the replication and proliferation of bacterial DNA, inhibiting bacterial growth and exerting bactericidal activity. It has been shown to inhibit the growth of canine-derived *E. coli* and *Pseudomonas aeruginosa* isolates, and is used in research related to bacterial infections.
- Antibiotic mechanism: Disrupts bacterial DNA replication and proliferation, leading to bactericidal activity.
- Target: Quinolone.
- Inhibits the growth of *Piscirickettsia salmonis* LF-89 VR-1361 (0.015-4.0 μg/mL) with sustained effect over 7 days.
- Induces post-antibiotic effect (PAE) and post-antibiotic sub-MIC effect (PA-SME) in clinical canine isolates.
- Exhibits concentration-dependent bactericidal activity against *Staphylococcus aureus* and time-dependent bactericidal activity against *Staphylococcus intermedius*.
Apexbio Technology LLC MI-2(Synonyms: Menin-MLL Inhibitor MI-2, MI2, MI 2, Menin inhibitor MI-2), 200mg, CAS: 1271738-62-5.
MI-2 (CAS 1271738-62-5) is a small molecule inhibitor targeting the menin-MLL protein-protein interaction with an IC50 of 0 45 M The formation of menin-MLL fusion protein complexes resulting from chromosomal rearrangements plays an essential role in the pathogenesis of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) MI-2 selectively binds wild-type menin disrupting its interaction with MLL-fusion proteins such as MLL-AF9 thereby inhibiting cellular proliferation and colony formation in MLL-AF9-transduced mouse bone marrow cells MI-2 serves as a research tool in studies of leukemia biology and menin-associated oncogenesis